- Title
- Why maximum tolerated dose?
- Creator
- Stampfer, Hans G.; Gabb, Genevieve M.; Dimmitt, Simon B.
- Relation
- British Journal of Clinical Pharmacology Vol. 85, Issue 10, p. 2213-2217
- Publisher Link
- http://dx.doi.org/10.1111/bcp.14032
- Publisher
- Wiley-Blackwell
- Resource Type
- journal article
- Date
- 2019
- Description
- A long‐established approach to the pharmacological treatment of disease has been to start low and go slow. However, clinicians often prescribe up to maximum tolerated dose (MTD), especially when treating acute and more severe disease, without evidence to show that MTD is more likely to improve outcomes. Cardiovascular guidelines for some indications advocate MTD even in prevention, for example hypercholesterolaemia, without compelling evidence of better outcomes. This review explores the origins and potential problems of prescribing medications at MTD. Oral effective dose 50 (ED50) may be a useful guide for balancing efficacy and safety.
- Subject
- clinical pharmacology; dosing outcomes; effective dose 50; maximum tolerated dose
- Identifier
- http://hdl.handle.net/1959.13/1416902
- Identifier
- uon:37136
- Identifier
- ISSN:0306-5251
- Rights
- This is the peer reviewed version of above article, which has been published in final form at https://doi.org/10.1111/bcp.14032. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
- Language
- eng
- Full Text
- Reviewed
- Hits: 3326
- Visitors: 3466
- Downloads: 165
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Author final version | 3 MB | Adobe Acrobat PDF | View Details Download |